米食品医薬品局(FDA)が、1つ以上のレジメンの治療歴がある慢性リンパ性白血病または小リンパ球性リ ンパ腫の治療薬として、一定の投与期間での選択的BCL-2阻害薬venetoclaxとリツキシマブ(遺伝子組換え)の併用療法を承認【FDA】

FDA approves venetoclax for CLL or SLL, with or without 17 p deletion, after one prior therapy


On June 8, 2018, the Food and Drug Administration granted regular approval to venetoclax (VENCLEXTA, AbbVie Inc. and Genentech Inc.) for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy.

出典:FDA
(リンク先外部サイト)

  

コメント

Leave a comment

Your email address will not be published.


*